Navigation Links
IU Confidential Publishes Biotech Investment Report
Date:7/28/2011

NEW YORK, July 28, 2011 /PRNewswire/ -- Investor Uprising Confidential, the premium investment research service of Investor Uprising, has published its "Best of Biotech: Innovation in Life Sciences" report today. The 16-page report covers the hottest trends in biotech investing, tells investors how to get involved, and gives an overview of more than 16 companies including a model portfolio of 10 top stock picks.

(Logo: http://photos.prnewswire.com/prnh/20110728/NY41230LOGO)

Biotech stocks have been among the best performers of the last five years, according to Investor Uprising Confidential's research, and many of these gains are driven by scientific innovation in the biopharmaceuticals and diagnostics markets. This innovation cycle is likely to continue for some time, making biotech an attractive place to invest.

"Many investors remain unaware of the strength in biotech and are mystified about how to invest in the market," says Investor Uprising Confidential's Editor and Publisher, R. Scott Raynovich. "Consequently, they have missed out. We put together a report that covers all the trends and explains many different ways to get involved, including ETFs, mutual funds, and individual stocks."

The report includes summaries of 17 leading biotechnology companies, three mutual funds, and the leading biotech Exchange Traded Funds (ETFs). Among the companies included in the report are Amgen Inc. (Nasdaq: AMGN), Biogen Idec  (Nasdaq: BIIB), Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Cubist Pharmaceuticals Inc. (Nasdaq: CBST), Dendreon Corp. (Nasdaq: DNDN), Illumina Inc. (Nasdaq: ILMN), and Seattle Genetics Inc. (Nasdaq: SGEN).

Investor Uprising Confidential produces premium in-depth reports aimed at informing the sophisticated investor about long-term trends in important growth markets. The Best of Biotech report is available as a single copy at $500, or as part of an Investor Uprising Confidential annual subscription. To look at the executive summary of the Biotech and the research service, go to http://www.investoruprising.com/confidential.

Sponsored by PR Newswire, Investor Uprising, as well as the recent launch of the "My News" feature on PRNewswire.com and monthly virtual Retail Investor Conferences (retailinvestorconferences.com), represents PR Newswire's strategy to facilitate engagement between the individual investor community and public companies.

About Investor Uprising

Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.

Media Contacts:
R. Scott Raynovich
Editor in Chief, Investor Uprising Confidential
(406) 582-5886 direct
(406) 599-7873 mobile
Scott.Raynovich@investoruprising.com

Noreen Seebacher
Community Editor, Investor Uprising
(201) 360-6773
Noreen.Seebacher@investoruprising.com


'/>"/>
SOURCE Investor Uprising
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
2. New Medical Supply Website Provides Confidentiality, Discounts for Consumers
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011
7. Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI
8. Cellectis Publishes Its Financial Statement for the First Half of 2010
9. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
10. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
11. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017  The particle counters ... by 2021 from USD 275.9 million in 2016, ... the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... on pharmaceutical R&D, and growth in manufacturing industries ... market growth for particle counters. On the other ...
(Date:2/24/2017)... CHEYENNE, Wyoming , Feb. 24, 2017  Xynomic ... company, today announced that it has acquired exclusive ... a potentially best-in-class innovative HDAC inhibitor targeting hematological ... total of 14 Phase 1 and 2 clinical ... Asia have already been completed, ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the celebrated ... Giveaway, with the winning couple announced on Feb. 14, 2017, on Facebook. The ... local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... a raffle. Throughout the month of February, patients who visit Hamlin Dental Group will ... a dinner for two at the Cheesecake Factory. , Tickets are available for ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads ... NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson Dentist ... an online directory that recognizes local physicians and dentists who have earned high ratings ...
Breaking Medicine News(10 mins):